Who owns Cardiff Oncology, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of CRDF from SEC Form 13F filings across 104 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 104 institutions disclosed 18.7M shares of Cardiff Oncology, Inc. worth $24.2M — about 27.4% of shares outstanding; the largest disclosed holder is Laurion Capital Management LP. Source: SEC Form 13F filings, parsed by EvidInvest.
104
13F holders
$24.2M
value, 2026 filers
27.4%
of shares outstanding (18.7M sh)
22
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of CRDF's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Laurion Capital Management LP | 3.1M | $4.0M | 0.1% | 4.5% | +17.1% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $3.8M | 0.0% | 4.2% | +1.4% |
| 3 | Pfizer Inc | 2.4M | $3.0M | 1.8% | 3.5% | 0.0% |
| 4 | FRANKLIN RESOURCES INC | 1.2M | $1.6M | 0.0% | 1.8% | 0.0% |
| 5 | BlackRock, Inc. | 972,873 | $1.3M | 0.0% | 1.4% | -75.6% |
| 6 | BLAIR WILLIAM & CO/IL | 912,513 | $1.2M | 0.0% | 1.3% | -1.1% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 820,062 | $1.1M | 0.0% | 1.2% | -48.7% |
| 8 | UBS Group AG | 638,699 | $830,309 | 0.0% | 0.9% | +59.4% |
| 9 | JANE STREET GROUP, LLC | 607,900 | $790,270 | 0.0% | 0.9% | +1415.8% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 410,602 | $533,783 | 0.0% | 0.6% | -8.0% |
| 11 | AQR CAPITAL MANAGEMENT LLC | 346,353 | $450,260 | 0.0% | 0.5% | +423.5% |
| 12 | STATE STREET CORP | 331,395 | $430,814 | 0.0% | 0.5% | -72.1% |
| 13 | HRT FINANCIAL LPNEW | 272,786 | $354,000 | 0.0% | 0.4% | new |
| 14 | FLPUTNAM INVESTMENT MANAGEMENT CO | 247,474 | $321,716 | 0.0% | 0.4% | -58.4% |
| 15 | MORGAN STANLEY | 246,095 | $319,924 | 0.0% | 0.4% | +337.1% |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 228,461 | $296,999 | 0.0% | 0.3% | +1647.2% |
| 17 | X-Square Capital, LLCNEW | 205,700 | $267,000 | 0.1% | 0.3% | new |
| 18 | GSA CAPITAL PARTNERS LLP | 173,274 | $225,000 | 0.0% | 0.3% | +40.9% |
| 19 | MARSHALL WACE, LLPNEW | 162,214 | $210,879 | 0.0% | 0.2% | new |
| 20 | Bank of New York Mellon Corp | 161,689 | $210,196 | 0.0% | 0.2% | -46.7% |
| 21 | NORTHERN TRUST CORP | 152,875 | $198,738 | 0.0% | 0.2% | -69.0% |
| 22 | Avestar Capital, LLC | 136,145 | $176,989 | 0.0% | 0.2% | 0.0% |
| 23 | MILLENNIUM MANAGEMENT LLC | 134,517 | $174,872 | 0.0% | 0.2% | +484.1% |
| 24 | Qube Research & Technologies LtdNEW | 125,550 | $163,215 | 0.0% | 0.2% | new |
| 25 | GOLDMAN SACHS GROUP INC | 120,827 | $157,076 | 0.0% | 0.2% | -10.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.